Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO

Posted by & filed under News.

PITTSBURGH, Oct. 28, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer of the company. Mr. Moch will also join the company’s Board of Directors. Mr. Moch brings to Cognition more than 25 years of experience in creating,… Read more »

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease

Posted by & filed under News.

PITTSBURGH, Sept. 29, 2016 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held, clinical stage pharmaceutical company focused on discovering and developing disease-modifying therapies for neurodegenerative diseases, announced today that, aided by a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), it will use its validated discovery platform to simultaneously discover drug… Read more »

US biotech Cognition Therapeutics tests Alzheimer’s drug in Australia

Posted by & filed under News.

The Australian, September, 18, 2015. Australia’s neuroscience expertise has convinced US company Cognition Therapeutics to launch a clinical study of a new Alzheimer’s drug in Melbourne, backed by a local female focused angel investor network. Susan Catalano, chief science officer at Cognition, said the exchange rate also helped with its decision to conduct the trial… Read more »

Cognition Therapeutics Commences Clinical Trials in Melbourne

Posted by & filed under News.

Scale Angels investee company Cognition Therapeutics commences clinical trials in Melbourne  Friday 18th September 2015. Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has commenced Phase 1 clinical studies in Melbourne. This study will examine the safety and pharmacokinetics of the company’s first-in-class oligomer… Read more »

Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing

Posted by & filed under News.

PITTSBURGH, Sept. 8, 2015 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has completed a Series B preferred stock financing totaling $12 million. Golden Seeds led the investment syndicate, which included, Bios Memory SPV1, Cowtown… Read more »

AlzForum covers CogRx publication of a new Abeta oligomer target and candidate therapeutics

Posted by & filed under News.

19 Dec 2014 Prion protein, insulin receptors, immunoglobulin-like receptors, PirB, unspecified membrane phospholipids, the list goes on … Now, add another purported Aβ receptor. At the Society for Neuroscience annual meeting in Washington, D.C., November 15 to 19, researchers led by Susan Catalano at the Pittsburgh-based biotech Cognition Therapeutics (CogRx) reported that Aβ interacts with the… Read more »

NIH to Fund CogRx’s Small Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD

Posted by & filed under News.

Cognition Therapeutics’ Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer’s Disease Selected for Support by National Institute on Aging/NIH Cooperative  agreement Program PITTSBURGH, May 21, 2014 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta… Read more »